Safety Results from the United States Cohort of the Ibrutinib Early Access Treatment Protocol (EAP: MCL4001) in Patients with Relapsed or Refractory Mantle Cell Lymphoma

被引：0

作者：

Martin, Peter ^{[1
]}

Goy, Andre ^{[2
]}

Ramchandren, Radhakrishnan ^{[3
]}

Ferrante, Lucille ^{[4
]}

Reddy, Vijay ^{[4
]}

Londhe, Anil ^{[4
]}

Wildgust, Mark ^{[5
]}

McGowan, Tracy ^{[4
]}

Bartlett, Nancy L. ^{[6
]}

机构：

[1] Weill Cornell Med Coll, New York, NY USA

[2] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[3] Karmanos Canc Ctr, Detroit, MI USA

[4] Janssen Sci Affairs LLC, Horsham, PA USA

[5] Janssen Global Serv, Raritan, NJ USA

[6] Washington Univ, Sch Med, St Louis, MO USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[41] Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma
Chari, Ajai
Mark, Tomer M.
Krishnan, Amrita
Stockerl-Goldstein, Keith
Usmani, Saad Z.
Londhe, Anil
Etheredge, Delores
Parros, Hollee
Fleming, Sarah
Liu, Baolian
Freeman, Scott
Ukropec, Jon
Lin, Thomas
Nooka, Ajay K.
BLOOD, 2016, 128 (22)
[42] THERAPY WITH BORTEZOMIB plus LENALIDOMIDE IS TOLERABLE IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (MCL): INTERIM RESULTS OF CALGB 50501
Morrison, V. A.
Jung, S.
Johnson, J.
Leonard, J.
Cheson, B.
ANNALS OF ONCOLOGY, 2011, 22 : 221 - 222
[43] Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)
Phillips, Tycel
Smith, Stephen D.
Jurczak, Wojciech
Robak, Tadeusz
Stevens, Don A.
Farber, Charles M.
Pagel, John M.
Maddocks, Kami
Flinn, Ian
Jedrzejczak, Wieslaw W.
Goy, Andre
Zinzani, Pier Luigi
Zaucha, Jan
Coleman, Morton
Chen, Tianling
Lee, Sun Ku
Liang, Wei
Seto, Anna
Wang, Michael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S317 - S317
[44] Real-World Effectiveness and Safety Outcomes of Acalabrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma
Patel, Krish
Teschemaker, Anna
Tian, Hongping
Pyrih, Nick
Kolvenbag, Geert
Patel, Shweta
Wahlstrom, Svea K.
Cui, Lianzhou
BLOOD, 2024, 144 : 7745 - 7745
[45] Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis
Rule, Simon
Dreyling, Martin
Goy, Andre
Hess, Georg
Auer, Rebecca
Kahl, Brad S.
Hernandez-Rivas, Jose Angel
Londhe, Anil
Clow, Fong
Deshpande, Sanjay
Parisi, Lori
Wang, Michael
BLOOD, 2017, 130
[46] Outcome of East Kent Hospitals University NHS Foundation Trust patients with relapsed/refractory Mantle Cell Lymphoma receiving Ibrutinib treatment
Seviar, D.
Young, M.
Capomir, M.
Lindsay, J.
Ratnayake, V.
Pocock, C.
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 181 - 181
[47] Evaluation of safety, tolerability and efficacy of Temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
Dreyling, M.
Hess, G.
Woike, M.
Krekeler, G.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 48 - 48
[48] Evaluation of safety, tolerability and efficacy of Temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
Dreyling, M.
Hess, G.
Krekeler, G.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 72 - 72
[49] Evaluation of safety, tolerability and efficacy of temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
Dreyling, M.
Krekeler, G.
Neuhof, A.
Woike, M.
Hess, G.
Kalanovic, D.
ANNALS OF ONCOLOGY, 2016, 27
[50] Evaluation of safety, tolerability and efficacy of temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
Dreyling, M. H.
Hess, G.
Woike, M.
Krekeler, G.
ANNALS OF ONCOLOGY, 2018, 29 : 362 - 362

← 1 2 3 4 5 →